Immunosuppressant Analogs in Neuroprotection:
In recent years there has been a growing recognition that such widely used immunosuppressant drugs as cyclosporin and FK-506 and their analogs-the neuroimmunophilins-possess significant neurotrophic and neuroprotective properties in addition to their beneficial effects for transplant patients. In Im...
Gespeichert in:
| Weitere Verfasser: | , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Totowa, NJ
Humana Press
2003
|
| Schlagworte: | |
| Online-Zugang: | DE-355 Volltext |
| Zusammenfassung: | In recent years there has been a growing recognition that such widely used immunosuppressant drugs as cyclosporin and FK-506 and their analogs-the neuroimmunophilins-possess significant neurotrophic and neuroprotective properties in addition to their beneficial effects for transplant patients. In Immunosuppressant Analogs in Neuroprotection, pioneers in the field and leading neuroscientists and clinicians working with these drugs survey the most recent scientific evidence showing how they evolved from being purely immunosuppressant "drugs" to neuroprotective "agents." These authorities focus on recent preclinical evidence that demonstrates the neurotrophic/neuroprotective effects of immunosuppressants when administered alone or when combined with neural transplantation therapy in animal models of neurological disorders. They discuss their efficacy and mechanisms of action in vitro and in vivo; using these models of CNS disease, they report laboratory studies with compelling clinical indications for Alzheimer's disease, Huntington's disease, stroke, traumatic brain injury, spinal cord injury, ALS, sciatic nerve injury, and drug addiction. They also present novel hypotheses on the mechanisms of neuroprotection, ranging from the blockade of mitochondrial permeability transition pores to free radical scavenging to the inhibition of calcineurin. Authoritative and cutting-edge, Immunosuppressant Analogs in Neuroprotection demonstrates that CsA, FK-506, and the immunophilins exert neuroprotective effects on their own and will serve well as a new breed of neuroprotective agents for the treatment of neurological disorders |
| Beschreibung: | 1 Online-Ressource (XXVII, 378 p) |
| ISBN: | 9781592593156 |
| DOI: | 10.1007/978-1-59259-315-6 |
Internformat
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046145678 | ||
| 003 | DE-604 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s2003 xx o|||| 00||| eng d | ||
| 020 | |a 9781592593156 |9 978-1-59259-315-6 | ||
| 024 | 7 | |a 10.1007/978-1-59259-315-6 |2 doi | |
| 035 | |a (ZDB-2-SME)978-1-59259-315-6 | ||
| 035 | |a (OCoLC)1119093782 | ||
| 035 | |a (DE-599)BVBBV046145678 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.8 |2 23 | |
| 084 | |a XI 6600 |0 (DE-625)153022:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Immunosuppressant Analogs in Neuroprotection |c edited by Cesario V. Borlongan, Ole Isacson, Paul R. Sanberg |
| 264 | 1 | |a Totowa, NJ |b Humana Press |c 2003 | |
| 300 | |a 1 Online-Ressource (XXVII, 378 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 520 | |a In recent years there has been a growing recognition that such widely used immunosuppressant drugs as cyclosporin and FK-506 and their analogs-the neuroimmunophilins-possess significant neurotrophic and neuroprotective properties in addition to their beneficial effects for transplant patients. In Immunosuppressant Analogs in Neuroprotection, pioneers in the field and leading neuroscientists and clinicians working with these drugs survey the most recent scientific evidence showing how they evolved from being purely immunosuppressant "drugs" to neuroprotective "agents." These authorities focus on recent preclinical evidence that demonstrates the neurotrophic/neuroprotective effects of immunosuppressants when administered alone or when combined with neural transplantation therapy in animal models of neurological disorders. They discuss their efficacy and mechanisms of action in vitro and in vivo; using these models of CNS disease, they report laboratory studies with compelling clinical indications for Alzheimer's disease, Huntington's disease, stroke, traumatic brain injury, spinal cord injury, ALS, sciatic nerve injury, and drug addiction. They also present novel hypotheses on the mechanisms of neuroprotection, ranging from the blockade of mitochondrial permeability transition pores to free radical scavenging to the inhibition of calcineurin. Authoritative and cutting-edge, Immunosuppressant Analogs in Neuroprotection demonstrates that CsA, FK-506, and the immunophilins exert neuroprotective effects on their own and will serve well as a new breed of neuroprotective agents for the treatment of neurological disorders | ||
| 650 | 4 | |a Neurology | |
| 650 | 4 | |a Neurology | |
| 650 | 0 | 7 | |a Immunsuppressivum |0 (DE-588)4161389-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Nervendegeneration |0 (DE-588)4300182-8 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Nervendegeneration |0 (DE-588)4300182-8 |D s |
| 689 | 0 | 1 | |a Immunsuppressivum |0 (DE-588)4161389-2 |D s |
| 689 | 0 | |8 1\p |5 DE-604 | |
| 700 | 1 | |a Borlongan, Cesario V. |4 edt | |
| 700 | 1 | |a Isacson, Ole |4 edt | |
| 700 | 1 | |a Sanberg, Paul R. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781468497427 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780896039445 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781468497410 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-1-59259-315-6 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-031525863 | |
| 966 | e | |u https://doi.org/10.1007/978-1-59259-315-6 |l DE-355 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1817718739773161472 |
|---|---|
| adam_text | |
| any_adam_object | |
| author2 | Borlongan, Cesario V. Isacson, Ole Sanberg, Paul R. |
| author2_role | edt edt edt |
| author2_variant | c v b cv cvb o i oi p r s pr prs |
| author_facet | Borlongan, Cesario V. Isacson, Ole Sanberg, Paul R. |
| building | Verbundindex |
| bvnumber | BV046145678 |
| classification_rvk | XI 6600 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-1-59259-315-6 (OCoLC)1119093782 (DE-599)BVBBV046145678 |
| dewey-full | 616.8 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.8 |
| dewey-search | 616.8 |
| dewey-sort | 3616.8 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-1-59259-315-6 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000zc 4500</leader><controlfield tag="001">BV046145678</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s2003 xx o|||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781592593156</subfield><subfield code="9">978-1-59259-315-6</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-59259-315-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-1-59259-315-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119093782</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046145678</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.8</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 6600</subfield><subfield code="0">(DE-625)153022:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immunosuppressant Analogs in Neuroprotection</subfield><subfield code="c">edited by Cesario V. Borlongan, Ole Isacson, Paul R. Sanberg</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Totowa, NJ</subfield><subfield code="b">Humana Press</subfield><subfield code="c">2003</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XXVII, 378 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In recent years there has been a growing recognition that such widely used immunosuppressant drugs as cyclosporin and FK-506 and their analogs-the neuroimmunophilins-possess significant neurotrophic and neuroprotective properties in addition to their beneficial effects for transplant patients. In Immunosuppressant Analogs in Neuroprotection, pioneers in the field and leading neuroscientists and clinicians working with these drugs survey the most recent scientific evidence showing how they evolved from being purely immunosuppressant "drugs" to neuroprotective "agents." These authorities focus on recent preclinical evidence that demonstrates the neurotrophic/neuroprotective effects of immunosuppressants when administered alone or when combined with neural transplantation therapy in animal models of neurological disorders. They discuss their efficacy and mechanisms of action in vitro and in vivo; using these models of CNS disease, they report laboratory studies with compelling clinical indications for Alzheimer's disease, Huntington's disease, stroke, traumatic brain injury, spinal cord injury, ALS, sciatic nerve injury, and drug addiction. They also present novel hypotheses on the mechanisms of neuroprotection, ranging from the blockade of mitochondrial permeability transition pores to free radical scavenging to the inhibition of calcineurin. Authoritative and cutting-edge, Immunosuppressant Analogs in Neuroprotection demonstrates that CsA, FK-506, and the immunophilins exert neuroprotective effects on their own and will serve well as a new breed of neuroprotective agents for the treatment of neurological disorders</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Immunsuppressivum</subfield><subfield code="0">(DE-588)4161389-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Nervendegeneration</subfield><subfield code="0">(DE-588)4300182-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Nervendegeneration</subfield><subfield code="0">(DE-588)4300182-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Immunsuppressivum</subfield><subfield code="0">(DE-588)4161389-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Borlongan, Cesario V.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Isacson, Ole</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sanberg, Paul R.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781468497427</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780896039445</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781468497410</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-59259-315-6</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031525863</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-59259-315-6</subfield><subfield code="l">DE-355</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV046145678 |
| illustrated | Not Illustrated |
| indexdate | 2024-12-06T19:01:16Z |
| institution | BVB |
| isbn | 9781592593156 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031525863 |
| oclc_num | 1119093782 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XXVII, 378 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 2003 |
| publishDateSearch | 2003 |
| publishDateSort | 2003 |
| publisher | Humana Press |
| record_format | marc |
| spelling | Immunosuppressant Analogs in Neuroprotection edited by Cesario V. Borlongan, Ole Isacson, Paul R. Sanberg Totowa, NJ Humana Press 2003 1 Online-Ressource (XXVII, 378 p) txt rdacontent c rdamedia cr rdacarrier In recent years there has been a growing recognition that such widely used immunosuppressant drugs as cyclosporin and FK-506 and their analogs-the neuroimmunophilins-possess significant neurotrophic and neuroprotective properties in addition to their beneficial effects for transplant patients. In Immunosuppressant Analogs in Neuroprotection, pioneers in the field and leading neuroscientists and clinicians working with these drugs survey the most recent scientific evidence showing how they evolved from being purely immunosuppressant "drugs" to neuroprotective "agents." These authorities focus on recent preclinical evidence that demonstrates the neurotrophic/neuroprotective effects of immunosuppressants when administered alone or when combined with neural transplantation therapy in animal models of neurological disorders. They discuss their efficacy and mechanisms of action in vitro and in vivo; using these models of CNS disease, they report laboratory studies with compelling clinical indications for Alzheimer's disease, Huntington's disease, stroke, traumatic brain injury, spinal cord injury, ALS, sciatic nerve injury, and drug addiction. They also present novel hypotheses on the mechanisms of neuroprotection, ranging from the blockade of mitochondrial permeability transition pores to free radical scavenging to the inhibition of calcineurin. Authoritative and cutting-edge, Immunosuppressant Analogs in Neuroprotection demonstrates that CsA, FK-506, and the immunophilins exert neuroprotective effects on their own and will serve well as a new breed of neuroprotective agents for the treatment of neurological disorders Neurology Immunsuppressivum (DE-588)4161389-2 gnd rswk-swf Nervendegeneration (DE-588)4300182-8 gnd rswk-swf Nervendegeneration (DE-588)4300182-8 s Immunsuppressivum (DE-588)4161389-2 s 1\p DE-604 Borlongan, Cesario V. edt Isacson, Ole edt Sanberg, Paul R. edt Erscheint auch als Druck-Ausgabe 9781468497427 Erscheint auch als Druck-Ausgabe 9780896039445 Erscheint auch als Druck-Ausgabe 9781468497410 https://doi.org/10.1007/978-1-59259-315-6 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Immunosuppressant Analogs in Neuroprotection Neurology Immunsuppressivum (DE-588)4161389-2 gnd Nervendegeneration (DE-588)4300182-8 gnd |
| subject_GND | (DE-588)4161389-2 (DE-588)4300182-8 |
| title | Immunosuppressant Analogs in Neuroprotection |
| title_auth | Immunosuppressant Analogs in Neuroprotection |
| title_exact_search | Immunosuppressant Analogs in Neuroprotection |
| title_full | Immunosuppressant Analogs in Neuroprotection edited by Cesario V. Borlongan, Ole Isacson, Paul R. Sanberg |
| title_fullStr | Immunosuppressant Analogs in Neuroprotection edited by Cesario V. Borlongan, Ole Isacson, Paul R. Sanberg |
| title_full_unstemmed | Immunosuppressant Analogs in Neuroprotection edited by Cesario V. Borlongan, Ole Isacson, Paul R. Sanberg |
| title_short | Immunosuppressant Analogs in Neuroprotection |
| title_sort | immunosuppressant analogs in neuroprotection |
| topic | Neurology Immunsuppressivum (DE-588)4161389-2 gnd Nervendegeneration (DE-588)4300182-8 gnd |
| topic_facet | Neurology Immunsuppressivum Nervendegeneration |
| url | https://doi.org/10.1007/978-1-59259-315-6 |
| work_keys_str_mv | AT borlongancesariov immunosuppressantanalogsinneuroprotection AT isacsonole immunosuppressantanalogsinneuroprotection AT sanbergpaulr immunosuppressantanalogsinneuroprotection |